10x Genomics Partners with CRI to Generate 20,000 Immune Data Samples
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy TXG?
Source: Newsfilter
- Project Launch: 10x Genomics collaborates with the Cancer Research Institute (CRI) to generate over 20,000 immune data samples aimed at advancing immuno-oncology, laying the groundwork for future immunotherapies and vaccine discoveries.
- Pilot Phase Goals: The initial phase targets the generation of approximately 3,000 samples, analyzed using 10x's Chromium and Xenium platforms, which will provide data support for benchmarking early AI models, enhancing the precision of immunotherapy.
- Large-Scale Sample Generation: Following the pilot's success, the project will expand to a broader network of laboratories, analyzing over 500 million cells, significantly increasing sample generation scale and driving the discovery and development of new therapies.
- Strategic Implications: This collaboration not only reinforces CRI's leadership in immunotherapy but also provides a new scientific foundation for cancer treatment, contributing to the vision of an “immune world against cancer.”
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TXG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 17.510
Low
9.00
Averages
13.00
High
18.00
Current: 17.510
Low
9.00
Averages
13.00
High
18.00
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
10x Genomics Q4 Earnings Beat Expectations
- Earnings Highlights: 10x Genomics reported a Q4 GAAP EPS of -$0.13, beating expectations by $0.08, indicating improved financial management despite still being in the negative territory.
- Revenue Growth: The company achieved Q4 revenue of $166 million, a 0.6% year-over-year increase, surpassing market expectations by $5.65 million, suggesting sustained acceptance of its products in the market.
- Future Outlook: 10x Genomics expects full-year 2026 revenue to range between $600 million and $625 million, although below the consensus of $611.77 million, it still reflects confidence in future growth, particularly with projected growth of 0% to 4% when excluding non-recurring license and royalty revenues from 2025.
- Market Reaction: Despite the earnings beat, shares fell by 3%, indicating market concerns regarding the company's growth potential, especially in light of weak spending in the U.S.
See More
10x Genomics Set to Release Q4 Earnings on February 12
- Earnings Announcement: 10x Genomics is scheduled to announce its Q4 2023 earnings on February 12 after market close, with consensus EPS estimated at -$0.04 and revenue expected at $160.35 million, reflecting a 2.8% year-over-year decline.
- Earnings Estimate Revisions: Over the past three months, EPS estimates have seen three upward revisions with no downward adjustments, indicating a growing confidence among analysts regarding the company's profitability.
- Revenue Estimate Adjustments: The revenue estimates have experienced ten upward revisions and one downward revision, suggesting a generally optimistic outlook for future revenue growth despite the company's overall sales performance being weaker.
- Market Performance Insights: While 10x Genomics' products are well-received, the weakness in U.S. spending continues to stifle growth, highlighting the challenges and opportunities the company faces in the current economic landscape.
See More
10x Genomics Fuels Creation of Major Cancer Dataset with AI Integration
- Dataset Construction: PharosAI will utilize 10x Genomics' Xenium spatial platform to create one of the world's largest multimodal cancer datasets, backed by £18.9 million in government funding, aimed at accelerating early diagnosis and precision therapies.
- Technical Collaboration: The research consortium comprises four leading UK institutions, combining clinical expertise with advanced technologies, planning to transform thousands of clinical tissue samples into high-resolution datasets to drive breakthroughs in cancer research.
- AI Model Application: By integrating genomic, transcriptomic, and spatial biology data, PharosAI will develop custom AI models that reveal hidden patterns in cancer research, thereby enhancing patient care and treatment outcomes.
- Open Data Sharing: The initiative will ensure secure access to datasets for a broad community of researchers and innovators, positioning the UK at the forefront of AI-driven cancer research and advancing the field of precision medicine.
See More
PHAROSAI AND 10X GENOMICS COLLABORATE TO REVOLUTIONIZE CANCER RESEARCH USING AI AND SPATIAL BIOLOGY
- Partnership Announcement: PHAROS AI and 10X Genomics have formed a partnership to enhance cancer research through advanced genomic technologies.
- Focus on Spatial Biology: The collaboration aims to integrate spatial biology techniques to better understand cancer mechanisms and improve treatment strategies.
See More
Historic Gold and Silver Price Collapse Triggers Mining Stock Selloff
- Historic Price Drop: On Friday, gold prices fell by 9.5% to $4,861 per ounce, while silver plummeted 27% to $84 per ounce, marking the largest single-day declines since 1980, leading to a sharp decrease in demand for precious metals and negatively impacting mining stocks.
- Mining Stocks Hit Hard: The collapse in gold and silver prices resulted in many mining stocks experiencing double-digit declines, reflecting a rapid loss of investor confidence in precious metals, prompting widespread sell-offs and putting pressure on the overall mining sector.
- Concerns Over Fed Independence Eased: The nomination of hawkish Kevin Warsh as the next Federal Reserve chair by President Trump has alleviated fears regarding the independence of the Fed, which may influence future monetary policy directions and investor sentiment.
- Increased Market Volatility: Warsh's criticism of modern monetary frameworks could inject new volatility into rate expectations; while this may promote short-term economic growth and employment, it also raises the risk of higher inflation in the long run.
See More
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
See More
10x Genomics Q4 Earnings Beat Expectations
- Earnings Highlights: 10x Genomics reported a Q4 GAAP EPS of -$0.13, beating expectations by $0.08, indicating improved financial management despite still being in the negative territory.
- Revenue Growth: The company achieved Q4 revenue of $166 million, a 0.6% year-over-year increase, surpassing market expectations by $5.65 million, suggesting sustained acceptance of its products in the market.
- Future Outlook: 10x Genomics expects full-year 2026 revenue to range between $600 million and $625 million, although below the consensus of $611.77 million, it still reflects confidence in future growth, particularly with projected growth of 0% to 4% when excluding non-recurring license and royalty revenues from 2025.
- Market Reaction: Despite the earnings beat, shares fell by 3%, indicating market concerns regarding the company's growth potential, especially in light of weak spending in the U.S.
See More
10x Genomics Set to Release Q4 Earnings on February 12
- Earnings Announcement: 10x Genomics is scheduled to announce its Q4 2023 earnings on February 12 after market close, with consensus EPS estimated at -$0.04 and revenue expected at $160.35 million, reflecting a 2.8% year-over-year decline.
- Earnings Estimate Revisions: Over the past three months, EPS estimates have seen three upward revisions with no downward adjustments, indicating a growing confidence among analysts regarding the company's profitability.
- Revenue Estimate Adjustments: The revenue estimates have experienced ten upward revisions and one downward revision, suggesting a generally optimistic outlook for future revenue growth despite the company's overall sales performance being weaker.
- Market Performance Insights: While 10x Genomics' products are well-received, the weakness in U.S. spending continues to stifle growth, highlighting the challenges and opportunities the company faces in the current economic landscape.
See More
10x Genomics Fuels Creation of Major Cancer Dataset with AI Integration
- Dataset Construction: PharosAI will utilize 10x Genomics' Xenium spatial platform to create one of the world's largest multimodal cancer datasets, backed by £18.9 million in government funding, aimed at accelerating early diagnosis and precision therapies.
- Technical Collaboration: The research consortium comprises four leading UK institutions, combining clinical expertise with advanced technologies, planning to transform thousands of clinical tissue samples into high-resolution datasets to drive breakthroughs in cancer research.
- AI Model Application: By integrating genomic, transcriptomic, and spatial biology data, PharosAI will develop custom AI models that reveal hidden patterns in cancer research, thereby enhancing patient care and treatment outcomes.
- Open Data Sharing: The initiative will ensure secure access to datasets for a broad community of researchers and innovators, positioning the UK at the forefront of AI-driven cancer research and advancing the field of precision medicine.
See More
PHAROSAI AND 10X GENOMICS COLLABORATE TO REVOLUTIONIZE CANCER RESEARCH USING AI AND SPATIAL BIOLOGY
- Partnership Announcement: PHAROS AI and 10X Genomics have formed a partnership to enhance cancer research through advanced genomic technologies.
- Focus on Spatial Biology: The collaboration aims to integrate spatial biology techniques to better understand cancer mechanisms and improve treatment strategies.
See More
Historic Gold and Silver Price Collapse Triggers Mining Stock Selloff
- Historic Price Drop: On Friday, gold prices fell by 9.5% to $4,861 per ounce, while silver plummeted 27% to $84 per ounce, marking the largest single-day declines since 1980, leading to a sharp decrease in demand for precious metals and negatively impacting mining stocks.
- Mining Stocks Hit Hard: The collapse in gold and silver prices resulted in many mining stocks experiencing double-digit declines, reflecting a rapid loss of investor confidence in precious metals, prompting widespread sell-offs and putting pressure on the overall mining sector.
- Concerns Over Fed Independence Eased: The nomination of hawkish Kevin Warsh as the next Federal Reserve chair by President Trump has alleviated fears regarding the independence of the Fed, which may influence future monetary policy directions and investor sentiment.
- Increased Market Volatility: Warsh's criticism of modern monetary frameworks could inject new volatility into rate expectations; while this may promote short-term economic growth and employment, it also raises the risk of higher inflation in the long run.
See More
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
See More
